This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Aclaris Therapeutics (ACRS) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris (ACRS) Surges: Stock Moves 5.4% Higher
by Zacks Equity Research
Aclaris (ACRS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Aclaris Gets FDA Nod to Start Investigator-led Coronavirus Study
by Zacks Equity Research
Aclaris (ACRS) announces that it supports an IND application to evaluate its oral investigational MK2 inhibitor compound, ATI-450, in hospitalized patients with COVID-19.
Will Aclaris Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Aclaris Therapeutics
All You Need to Know About Aclaris (ACRS) Rating Upgrade to Buy
by Zacks Equity Research
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris (ACRS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I
by Zacks Equity Research
Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.
Aclaris (ACRS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rigel Gets Positive CHMP Review for Thrombocytopenia Drug
by Zacks Equity Research
The CHMP advocates Rigel's (RIGL) marketing approval for Tavalisse to treat chronic immune thrombocytopenia in Europe.
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Oct 17, 2019
by Zacks Equity Research
Companies In The News Are: GM, ACRS, MGM, AVD
Aclaris Divests Rhofade to EPI Health for $55M, Shares Up
by Zacks Equity Research
Aclaris (ACRS) divests worldwide rights to its rosacea drug, Rhofade, to privately-held EPI Health as part of its restructuring program.
Top Ranked Momentum Stocks to Buy for October 3rd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, October 3rd.
Top Ranked Momentum Stocks to Buy for September 27th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, September 27th.
Aclaris Therapeutics, Inc. (ACRS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aclaris Therapeutics, Inc. (ACRS).
Aclaris (ACRS) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Pacira (PCRX) rides high on both earnings and revenue beat in the second quarter of 2019. Moreover, Exparel drives year-over-year growth.
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aclaris (ACRS) delivered earnings and revenue surprises of 6.49% and 1.65%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance
by Zacks Equity Research
Zoetis (ZTS) beats on earnings and sales in the second quarter and also raises its 2019 outlook.
Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aclaris Therapeutics Enters Oversold Territory
by Zacks Equity Research
Aclaris Therapeutics has been on a bit of a cold streak lately.
What Makes Aclaris (ACRS) a New Buy Stock
by Zacks Equity Research
Aclaris (ACRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rigel Initiates Enrollment in Pivotal Blood Disorder Study
by Zacks Equity Research
Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.